Sherrill, J D
KC, K
Blanchard, C
Stucke, E M
Kemme, K A
Collins, M H
Abonia, J P
Putnam, P E
Mukkada, V A
Kaul, A
Kocoshis, S A
Kushner, J P
Plassard, A J
Karns, R A
Dexheimer, P J
Aronow, B J
Rothenberg, M E
Article History
Received: 7 March 2014
Revised: 23 April 2014
Accepted: 24 April 2014
First Online: 12 June 2014
Competing interests
: MER is a consultant for Immune Therapeutics and has an equity interest in reslizumab (Teva Pharmaceuticals) and is a consultant for Immune Pharmaceuticals, Pluristem Pharmaceuticals, Novartis and Receptos. The remaining authors declare no conflict of interest.